| Revenue Growth | Total revenue up 27% to $275.4M; molecular profiling up 27% to $262.7M. |
|---|---|
| Mgmt Confidence | High confidence in commercial strategy and accelerating volume growth trends into Q4. |
| Demand Visibility | Strong momentum with 65,000 cases expected in Q4; 75% orders via EMR. |
| Margin Trends | Gross margin at 66%; sixth consecutive quarter of positive adjusted EBITDA. |
| Op. Leverage | Operating expenses grew 48% to $163M, funding sales force and marketing. |
| Pricing Power | Blended ASP $4,272 up 5%; base ASP $3,990 up 19% pre-true-ups. |
| Vol vs Price | Growth driven by 21% volume increase and 19% pre-true-up ASP expansion. |
| Segment Growth | Clinical therapy selection volume grew 21%; R&D services revenue up 37%. |
| New Clients | Precision Oncology Alliance expanded to 102 sites; 3,500 physicians ordering via EMR. |
| Capex & Debt | CapEx of $17.5M; $769M cash; $10M stock repurchased in Q3. |
| Regulatory | PAMA rate for Caris Assure increased to $5,250 effective January 2027. |
| Commentary | Philosophy of 'deeper not cheaper' prioritizing comprehensive 23,000-gene whole exome sequencing. |
| New Launches | Launched Caris Assure monitoring; Caris Confirm MRD launch scheduled for December. |
Growth
Total revenue grew 27% to $275.4M; clinical volume rose 21% to 61,500 cases.
Outlook
Raised FY2026 revenue guidance to $1.04B-$1.05B; targeting 65,000 clinical cases in Q4.
Risks
Management evaded specific volume/revenue breakouts for new products like Caris Detect and Chromoseq.
The company's earnings call, NASDAQ: CAI, and its 8-K filed with the SEC. Summary written with AI assistance from the call.
Earnings call webcast ↗ Watch on YouTube ↗
Caris Life Sciences, Inc.: key numbers
- Share price
- $21.00Close, Nov 16
- Market cap
- $6.02B
- Shares outstanding
- 286.78MLatest SEC cover page
- Sector
- Industrial Applications and Services
- Industry
- Services-Medical LaboratoriesSIC 8071
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Caris Life Sciences, Inc.
All →Caris Life Sciences Q3 2026 Results: Net Income $15.2M, Down 37.3% YoY
Caris Life Sciences reported total revenue of $755.2 million for the nine months ended September 30, 2026, a significant increase from $519.1 million in the prior year period. The company achieved a net income from operations of $51.5 million for the first nine months of 2026, compared to an operating loss of $43.3 million in 2025, driven primarily by growth in molecular profiling services.
- Key figure
- Net income $15.2M · -37.3% YoY
Caris Life Sciences Financial Results
Caris Life Sciences reported Q3 2026 revenue of $275.4 million, a 27% increase year-over-year, driven by strong molecular profiling clinical case volume. The company raised its full-year 2026 revenue guidance to a range of $1.04 billion to $1.05 billion and reported positive net income of $15.3 million for the quarter.
- Term
- Q3 2026
“This was another record quarter, with approximately 61,500 clinical cases, up 21% year over year. Every case we run carries real molecular depth, whether Whole Exome, Whole Transcriptome, Whole Genome, or AI-driven digital pathology, and that depth is what allows us to move across the entire cancer journey.”
David Dean Halbert, Founder, Chairman and CEO
Caris Life Sciences Investor Presentation
Caris Life Sciences announced that its management team will use a formal investor presentation for meetings with current and potential investors at the Morgan Stanley 24th Annual Global Healthcare Conference beginning September 14, 2026. The presentation will be made available on the company's investor relations website.
- Counterparty
- Morgan Stanley 24th Annual Global Healthcare Conference